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Abstract
Randomised trials are at the heart of evidence-based healthcare, but the methods and infrastructure for conducting
these sometimes complex studies are largely evidence free. Trial Forge (www.trialforge.org) is an initiative that aims
to increase the evidence base for trial decision making and, in doing so, to improve trial efficiency.
This paper summarises a one-day workshop held in Edinburgh on 10 July 2014 to discuss Trial Forge and how to
advance this initiative. We first outline the problem of inefficiency in randomised trials and go on to describe Trial
Forge. We present participants’ views on the processes in the life of a randomised trial that should be covered by
Trial Forge.
General support existed at the workshop for the Trial Forge approach to increase the evidence base for making
randomised trial decisions and for improving trial efficiency. Agreed upon key processes included choosing the
right research question; logistical planning for delivery, training of staff, recruitment, and retention; data
management and dissemination; and close down. The process of linking to existing initiatives where possible was
considered crucial. Trial Forge will not be a guideline or a checklist but a ‘go to’ website for research on
randomised trials methods, with a linked programme of applied methodology research, coupled to an effective
evidence-dissemination process. Moreover, it will support an informal network of interested trialists who meet
virtually (online) and occasionally in person to build capacity and knowledge in the design and conduct of efficient
randomised trials.
Some of the resources invested in randomised trials are wasted because of limited evidence upon which to base
many aspects of design, conduct, analysis, and reporting of clinical trials. Trial Forge will help to address this lack of
evidence.
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Background
‘There is a peculiar paradox that exists in trial
execution - we perform clinical trials to generate
evidence to improve patient outcomes; however, we
conduct clinical trials like anecdotal medicine: (1) we
do what we think works; (2) we rely on experience and
judgement and (3) limited data to support best
practices.’
Monica Shah, quoted in Gheorghiade et al. [1].
This paper summarises a one-day workshop held in
Edinburgh on 10 July 2014 to discuss Trial Forge
(www.trialforge.org), an initiative focused on improving
randomised trial efficiency and quality. The initiative is
aimed at the people who design and run trials, staff at
trials units, for example, or clinicians and others who
design studies. In this paper, we outline the problem of
inefficiency in trials and describe the Trial Forge initia-
tive to improve efficiency. We hope that many of those
reading the paper will be interested in contributing to
Trial Forge in the future.
Randomised trials (hereafter ‘trials’), especially when
brought together in systematic reviews, are regarded as
the gold standard for evaluating the effects of healthcare
treatments, with thousands of trials and hundreds of sys-
tematic reviews reported every year. PubMed has
indexed over 370,000 reports of randomised trials; the
World Health Organisation’s International Clinical Trials
Registry Platform [2] contains over 250,000 trial records,
of which, 71,000 are listed as recruiting; and the Cochrane
Central Register of Controlled Trials contains more than
800,000 records. Tens of billions of dollars of public and
private money are invested globally in trials every year (US
$25 billion in the United States alone in 2010 [3]) and the
average cost of a trial per participant is estimated to be
almost £8,500 in the United Kingdom [4].
Many of these resource are wasted, often because in-
sufficient account is taken of existing evidence when
choosing questions to address [5], and results are either
not published or poorly reported. Moreover, despite tri-
als being a cornerstone of evidence-based healthcare, the
methods and infrastructure for conducting these com-
plex studies are largely evidence free [6]. For example,
every trial has to recruit and retain participants, but only
a handful of recruitment and retention strategies and in-
terventions are currently supported by high-quality evi-
dence [7, 8]. A recent analysis found that only 55 % of
UK National Institute of Health Research and Medical
Research Council (MRC) trials (a set of large, relatively
well-funded studies in the UK) recruiting between 2002
and 2008 met their recruitment targets [9]. The same
study found that extensions are common, with 45 % of
trials needing at least one funding extension, although
only 55 % of these then go on to meet their recruitment
targets. Furthermore, although data collection is central
to trials and can consume a large proportion of trial re-
sources, researchers often collect more data than they
are able to analyse and publish [10]. Indeed, there is a
dearth of research into the optimal methods for data col-
lection and data management [11]. This is a different
problem from selective reporting, where bias is introduced
through the way outcomes are selected and presented in
trial reports, especially for harms [12]. Vera-Badillo and
colleagues called this type of bias ‘spin’ [13].
As a consequence, the most appropriate methods are
not always chosen when trials are designed, leading to
trial management and delivery problems later. Indeed,
poor design decisions may do more than make a trial
difficult to deliver; they may mean that any eventual
findings will be of limited value. This could be because,
for example, the comparator used renders the trial clin-
ically irrelevant [14], the outcome measures are not rele-
vant to those making treatment decisions [15], or the
patients involved do not represent the majority of pa-
tients with the condition of interest [16]. The patients,
health professionals, and policymakers who look to sys-
tematic reviews of trials for help in their decision making
are often frustrated to find that the questions addressed
by researchers do not reflect clinical decision making
needs (a failure of prioritisation) [17], have dubious rele-
vance in their settings [17–19], or that failings in the con-
duct or reporting of trials mean that they do not provide
the reliable and robust evidence that they need. Some tri-
als may simply be unnecessary [20]. This all represents an
unacceptably wasteful approach to designing, running,
analysing, and reporting trials. The problem of inefficiency
in medical research is not new: Schwartz and Lellouch
urged trialists to change the way they designed trials as
long ago as 1967 [21], Altman pointed to the scandal of
poor medical research in 1994 [22], and, in 2009 [23],
Chalmers and Glasziou estimated that more than 85 % of
the resources invested in medical research was being
avoidably wasted. What has been lacking is a coordinated
attempt to tackle inefficiency in clinical trials.
Main text
Trial Forge
Trial Forge (www.trialforge.org) aims to address the lack
of an accessible evidence base around trial efficiency and
quality. A one-day workshop, funded by the Network of
MRC Hubs for Trials Methodology Research and the
Health Services Research Unit at the University of
Aberdeen, UK, was held in Edinburgh on 10 July 2014
to discuss the initiative. The grant holders of the MRC
Hub funding (Marion Campbell, Mike Clarke, Athene
Lane, Trudie Lang, John Norrie, Shaun Treweek, and
Paula Williamson) invited 38 participants with experience
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in methodology and trial design, trial management, statis-
tics, data management, clinical care, commissioning and
publishing research, public and patient involvement, and
providing trial support through trials units to the worship.
The aims of the workshop were as follows:
1. To share knowledge on resources that already exist
with regard to efficient trials.
2. To share knowledge on guidance relating to trial
design, conduct, analysis, and reporting.
3. To agree on the key processes of the trial pathway,
that is, the major processes in the life of a trial.
4. To begin to suggest features that Trial Forge must
have.
5. To promote awareness of Trial Forge.
6. To produce a statement paper on the Trial Forge
initiative
As the workshop members were professional trialists,
trial managers, statisticians, and others involved in trial
design, conduct, analysis, and reporting and the discus-
sions were of current practice, no formal ethics approval,
or consent was deemed necessary.
How will Trial Forge work?
Discussion at the workshop highlighted several substan-
tial problems, some of which are listed in Table 1. Trial
Forge aims to remove or reduce these problems and
others through targeted collaborative work. Some of the
ways it will do this are listed in Table 1. Trial Forge will
use a five-step process to identify and address gaps in
knowledge about trial method:
1. Identify trial processes
2. Collate what is known about these processes.
3. Strengthen the evidence base by creating a
methodology research agenda.
4. Collaborate to work through the methodology
research agenda.
5. Dissemination.
Step 1 - Identify trial processes
Step 1 will identify the processes that make up a trial,
starting with the main processes (for example, recruit-
ment) and then breaking these down into smaller pro-
cesses (for example, how to set the eligibility criteria for
a trial, selecting the components of the recruitment
strategy, identifying potential participants, and targeting
appropriate recruitment strategies for them). This is
similar to the process improvement approach taken by
the British cycling team in its preparation for the 2012
London Olympic Games. Dave Brailsford, British Cycling's
Performance Director at the time said when asked about
the team’s approach:
‘The whole principle came from the idea that if you
broke down everything you could think of that goes
into riding a bike, and then improved it by 1 %, you
will get a significant increase when you put them all
together.’ [24]
There are very many processes involved in a trial, and
learning about, and improving each of them may have a
minimal effect on its own, but taken together, these im-
provements could have a much more profound impact.
Participants at the Edinburgh workshop produced an
initial list of headline trial processes (Fig. 1) for which
collating (and creating) research evidence would be
beneficial. This list will form the starting point for Trial
Forge work.
Step 2 - Collate what is known about these processes
In Step 2, Trial Forge will either identify existing initia-
tives to collate what is known about individual processes
or work to collate the evidence (which may include pro-
viding links to ongoing studies) and integrate reviews
(and other relevant literature) using both quantitative
and qualitative synthesis approaches [25–28]. For ex-
ample, for help in choosing trial outcomes, Trial Forge
would direct people towards the COMET (Core Out-
come Measures in Effectiveness Trials [29], http://
www.comet-initiative.org) Initiative. COMET has sys-
tematically reviewed published standardised core out-
come sets for trials [30], and combined these in the
COMET database with information on core outcome
sets currently being developed. As another example, for
help with choosing evidence-based recruitment inter-
ventions, the MRC Network of Hubs for Trials Method-
ology Research is funding a project to develop a
searchable database containing published and ongoing
research into recruitment. On a smaller scale, Cochrane
Methodology Reviews, and other systematic reviews
have brought together existing research in specific topic
areas. These will be highlighted in Step 2. Epistemonikos
(http://www.epistemonikos.org/en/), a website that links
together systematic reviews, overviews of reviews, and
primary studies to support health-policy decisions, is an-
other example of how research evidence can be collated.
More generally, the Evidence-Based Research Network
(http://www.ebrnetwork.org) is an example of an initia-
tive that aims to promote the efficient use of existing re-
search, especially through the use of systematic reviews
[31] and information about ongoing research. Proposals
for new research should be informed by systematic re-
views, and reports of new research should be set in the
context of updated systematic reviews.
Trial Forge will aim to apply quality criteria when
pointing to external resources and when collating indi-
vidual studies. How to do this will form part of the
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Table 1 Trial Forge Examples of trial challenges and how Trial Forge could help
General problem Examples Examples of how Trial Forge aims to help
Information is spread over many journals,
websites, books and other publications, which
makes it difficult to access and use in decision
making. This makes finding and navigating the
literature time-consuming and challenging.
Searching Pubmed [http://
www.ncbi.nlm.nih.gov/sites/entrez/, searched 2
Jan 2015] using the phrase clinical trial
recruitment and limiting to reviews in the last 5
years produces 252 hits, too large a number to
sift through easily.
To collate, or link people to, existing high-
quality evidence on key trial processes. For re-
cruitment this would include: what influences
recruitment strategies that can improve recruit-
ment how to tailor recruitment strategies to par-
ticular contexts
A search on Google Scholar [http://
scholar.google.com, searched 2 Jan 2015] using
the same phrase (exact phrase search) produces
1080 hits since 2010.
To develop targeted research agendas designed
to fill gaps in knowledge around how best to
recruit trial participants.
Searching Amazon [http://www.amazon.co.uk
searched 2 Jan 2015] for clinical trial recruitment
produces 525 hits; the first page results of
includes books costing less than £1 to over
£900.
To make it easier for teams to work together to
address these research agendas.
In the absence of high-quality evidence, provide
a repository for the experience and knowledge
from the community of trialists as to how they
recruit participants.
There are substantial gaps in the evidence base
for key issues that affect all trials and which are
not being systematically targeted by
methodology research.
There is little published research evidence to
inform decisions about trial management
options such as how best to select clinical sites,
how to maintain relationships with sites, how to
model the movement of patients and staff
through trial processes, or how to effectively
train trial and site staff.
To develop targeted research agendas designed
to fill gaps in knowledge about how to design,
run, analyse and report trials.
For trial management, the development of
methods to allow trial managers to share their
solutions without the need for full publications,
which are not generally part of the career
development of trial managers (ie. there is no
incentive to publish).
Encourage systematic reviewers (eg. of
Cochrane reviews) to suggest concrete
methodological studies that need to be done
and to link these to initiatives such as SWATs
[43, 44] to provide ready-made protocols for
those studies.
Systematically direct information about evidence
gaps to funding agencies for their consideration
as part of their prioritisation process for the
selection of topics for funding calls.
Much trial knowledge is tacit and held by
experienced staff working at trials units, other
similar centres, or on individual trials.
Although many research groups and units cost,
manage and create data management systems
for trials, there is little easily available
information on effective ways of how to
complete each of these processes.
In the absence of high-quality evidence, provide
a repository for the experience and knowledge
from the community of trialists as to how they
design, run, analyse and report their trials.
Collate and evaluate tools that are being used
by groups designing and running trials such as
trials units and other similar centres.
To develop targeted research agendas designed
to move from tacit, often unevaluated
knowledge, to high-quality evaluated evidence.
There is no easy way for individuals needing
advice to access it from the potentially
thousands of people who have knowledge that
might help them.
If a trial data management team using the
OpenClinica system encounters a technical
problem, there is an active online community
that provides help free (https://
community.openclinica.com). Questions are
answered quickly. There are few similar
opportunities to quickly address questions on
trial design, conduct, analysis or reporting.
Provide a repository for the experience and
knowledge from the community of trialists as to
how they design, run, analyse and report their
trials.
Provide support for electronically linked
communities of practice (e.g. through Question
& Answer and discussion sections on its
website)
Learn from The Global Health Network (https://
tghn.org) on how to build online communities
in healthcare.
Information is not structured in a way that helps
people find what they need to resolve their
uncertainties. People working on trials have
questions (such as ‘Should I visit the sites to
boost recruitment?’, ‘How much quality
The Clinical Trials Toolkit (http://www.ct-
toolkit.ac.uk/routemap) provides regulatory and
other information about drug trials in the UK
Although useful, the information is structured
like a text book. People visiting the site,
Provide a mixed structure to Trial Forge, where
much of the material is directly framed as
questions and answers. Where evidence
provides a clear answer, this information will be
presented as a question.
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Table 1 Trial Forge Examples of trial challenges and how Trial Forge could help (Continued)
assurance do I need to do?’, ‘Will adding an
extra outcome measure affect recruitment and
retention?’), but guidance is rarely organised
around questions and the answers to them.
however, are likely to have done so because
they have a series of questions about their trial
and are looking for answers. The textbook
structure makes answering these questions
slower than it could be.
Work with trialists to present information in
such a way that it enables them to find answers
to their questions as quickly as possible.
There is no easy way to support collaborative,
trial methodology research to address evidence
gaps and shortcomings.
The 2010 Cochrane review of interventions to
improve trial recruitment [7] includes 45 trials
evaluating 46 interventions. Despite this, the
review concludes that there is high-quality evi-
dence supporting only three or so interventions.
The effectiveness or otherwise of the other in-
terventions remains unclear.
The initiatives listed above will help to identify
gaps in evidence. Trial Forge will then highlight
these, including to funders in an effort to focus
researcher effort on important and known gaps.
By supporting SWATs [43, 44], researchers
wishing to fill at least some of these gaps will
be able to use existing (and common) protocols
to evaluate given interventions.
Provide electronically linked communities that
can agree to work together to fill a gap by, for
example, evaluating the same intervention
across many trials. A good example of this
approach is the MRC START project for
recruitment interventions: http://
www.population-health.manchester.ac.uk/
mrcstart/
Fig. 1 Key processes of the trial pathway (many of which are overlapping and non-linear). Suggestions from a one-day workshop held in Edinburgh
on 10 July 2014. The placement and length of the bars gives an indication of when in the trial they start and end, though this is likely to vary greatly
between trials
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initial work of Trial Forge, though it is likely that
GRADE [32] (a system for grading the quality of evi-
dence and the strength of recommendations, particularly
for guidelines) will contribute importantly. Different ap-
proaches to presenting evidence will be explored using
methods developed by the GRADE Working Group
where appropriate, and the methods used to present the
information will be informed by work done with, among
others, the Cochrane Plain Language Summaries [33],
the GRADE Summary of Findings tables [34, 35], and
the DECIDE project (a project that aims to improve the
way research information is presented in guidelines,
http://www.decide-collaboration.eu). This presentation
work will also be evaluated.
Step 3 - Strengthen the evidence base by creating a
methodology research agenda
Step 3 will focus on strengthening the evidence base by
providing a platform to highlight key areas of uncer-
tainty, which would enable individuals and research
groups to suggest ways in which the uncertainties could
be addressed. For example, we know less about the effect
of recruitment interventions aimed at recruiters than we
do about those aimed at potential participants [7]. Re-
cruiters play a hugely influential role and can have a
substantial impact on recruitment [36, 37], but there re-
mains uncertainty about how best to address the issues
and concerns that recruiters face [36–45]. One way to
help fill this gap (and others) may be through the avail-
ability of standard outlines for Studies Within A Trial
(SWATs). The design of SWAT-1 is for site visits by the
principal investigator to increase or maintain recruit-
ment [46].
Publishing protocols for methodology research, which
can then be embedded in other studies, makes it easier
for research groups to become involved in filling evi-
dence gaps. Much of the intellectual work around the
appropriate methodology research already will have been
done by the authors of the protocol. A database of out-
lines for SWATs is being developed to improve access to
these ideas [47]. Step 3 of Trial Forge will produce
SWATs as well as link people to initiatives such as the
MRC-funded Systematic Techniques for Assisting
Recruitment to Trials (START) programme (http://
www.population-health.manchester.ac.uk/mrcstart/), which
is developing a platform to evaluate recruitment interven-
tions simultaneously across many trials.
Finally, where evidence does not yet exist, information
about these gaps will be systematically directed to funding
agencies for consideration in their prioritisation processes.
In the meantime, Trial Forge will provide a repository for
experience and knowledge from the community of trial-
ists, trial managers, and others about interventions and
approaches that they believed worked well in their
settings. Trial Forge will thus provide support for elec-
tronically linked communities of practice (for example,
through question and answer and discussion sections on
its website) to facilitate sharing of knowledge and experi-
ences, especially when rigorous evidence to inform deci-
sions is lacking.
Step 4 - Collaborate to work through the methodology
research agenda
A methodology research agenda will have been created
in Step 3. Step 4 will encourage wide collaboration
among methodologists, trialists, and other relevant
stakeholders to tackle this research agenda. For some
processes in the trial pathway (Fig. 1), the agenda will be
substantial and very challenging. A single research group
or trials unit is unlikely to have the skills, capacity, or
interest to take on a whole agenda. By bringing research
groups together around a shared agenda, Trial Forge will
minimise unnecessary duplication, focus work on topics
shown to be most in need of attention (with a recent
survey of the priorities of UK Clinical Trials Unit Direc-
tors providing a good starting point [48]), and identify
groups with the necessary expertise to do the work. For
example, groups could work together to evaluate an
intervention described in a SWAT. This collaboration
between groups may happen naturally through direct
contact but could be facilitated by Trial Forge, for ex-
ample by having a coordinator identify potential links
and encouraging collaboration.
Step 5 - Dissemination
The value of the expanded evidence base will be realised
in Step 5: when Trial Forge has identified or generated
an important result from, for example, an up-to-date
systematic review of relevant methodology research,
people who need to know about it should be informed
efficiently. For example, if, as a result of including new
trial data to the Cochrane review of interventions to im-
prove retention in trials [8] meant that there was now
clear evidence that a particular intervention was effect-
ive, Trial Forge would help to ensure that this informa-
tion is disseminated efficiently to trialists. A variety of
dissemination routes will be used, for example, elec-
tronic mailing lists, a Twitter feed, presentations at the
UK Clinical Trials Units Directors’ meetings and training
courses. Dissemination routes are likely to need to
change over time and may well need to differ depending
on the trial process being addressed. An underlying
principle will be that simply publishing the findings in a
journal article is unlikely to be sufficient to promote up-
take. To maximise the impact of this methodology re-
search, Trial Forge will use evidence from implementation
research to promote clinical and professional behaviour
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change interventions [49]. This step of Trial Forge will
also be evaluated.
The five steps in Trial Forge will be iterative, especially
since many trial processes are linked and because sug-
gestions for change in one area may have consequences
for others. Trial Forge’s own processes will also be evalu-
ated and modified over time as we and others learn from
our experience of using the five steps to reduce gaps in
knowledge about how best to design, conduct, analyse,
and report trials. Once started, Trial Forge should pro-
duce a steady stream of methodology innovations that
address trial process problems of recognised significance
to people involved in trials. Importantly, work, and prestige
will not be concentrated in one place or group but will be
distributed across a collaborative network. Groups engaging
with Trial Forge will be encouraged to build up their own
portfolios of methodology work in areas that match their
interests and expertise.
Conclusion
Trial Forge aims to support active and regular engage-
ment with people who design, conduct, analyse, and re-
port trials in the UK and elsewhere. It will promote
meaningful improvements in trial efficiency and greater
potential for trials to improve health. Moreover, Trial
Forge will support an informal network of interested tri-
alists, who will meet virtually and occasionally in person
to build capacity and knowledge in efficient trials design
and conduct. It will aim to be the ‘go to’ website for
summaries of what is known about trial methods re-
search but also for a linked programme of applied meth-
odology research that encourages people to collaborate
to fill gaps in evidence.
Not all problems in trials need more methodology
research. However, many aspects of trial design, con-
duct, analysis, and reporting could be subjected to re-
search to identify the relative effects of alternative
approaches and whether these aspects are scientific,
methodological, or administrative; they all have uncer-
tainties that could be addressed by research leading to
greater evidence-based approaches than is currently
the case. We believe that Trial Forge will maximise
the effectiveness and efficiency of trials, increase the
chances that they will produce reliable and robust an-
swers, and minimise waste. Trialists share many of the
same problems; Trial Forge is about working together
to solve them.
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